Login Register Cart 0
CNS & Neurological Disorders - Drug Targets

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Insights into the Diagnosis, Treatment, and Management of Prion Diseases

Author(s): Vania Austine Callistaorcid of author, Ketan Vinayakrao Hatware*orcid of author and Pravinkumar Vishwanath Ingleauthors OrcID

Volume 25, Issue 1, 2026

Published on: 08 July, 2025

Page: [25 - 38] Pages: 14

DOI: 10.2174/0118715273381241250620114740

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

The normal cellular prion protein (PrPC) can misfold into an infectious and pathogenic form (PrPSc) to produce prion diseases, also known as transmissible spongiform encephalopathies (TSEs), which are rare and deadly neurodegenerative conditions. The conversion of PrPC to PrPSc, which builds up as toxic aggregates in the central nervous system, is caused by sporadic, inherited, or acquired pathways. PrPSc-induced proteostasis failure, oxidative stress, neuronal toxicity, and progressive neurodegeneration are characteristics of pathogenesis. Due to their overlap with other neurodegenerative illnesses, prion diseases are still difficult to diagnose, even with breakthroughs in our knowledge of the molecular causes. Cerebrospinal fluid biomarkers, neuroimaging, EEG, and genetic testing are utilized in the diagnostic process. Methods like real-time quaking-induced conversion (RT-QuIC) provide high sensitivity. As there are currently no cures, the main goals of management are palliative care and symptom alleviation. Research is currently being conducted on experimental strategies that target PrP misfolding. These strategies include autophagy enhancers, monoclonal antibodies, antisense oligonucleotides, and small compounds. Artificial intelligence (AI) shows revolutionary promise by enhancing early diagnosis through biomarker analysis, neuroimaging interpretation, and EEG pattern identification. AI also improves clinical trial design, identifies tailored treatment approaches, and accelerates drug discovery. Furthermore, advancements in AI-based bioinformatics technologies have led to a better understanding of prion biology and strain diversity. The future holds promise for utilising cutting-edge treatment techniques, such as CRISPR and gene therapy, for targeted interventions, as well as combining AI with multimodal data to enhance diagnostic capabilities. There is optimism that the burden of prion disorders can be reduced, and the treatment of neurodegenerative illnesses can be improved through the integration of molecular research, novel treatments, and AI technology.

Keywords: Artificial intelligence, gene therapy, management, neurodegenerative disorder, pathogenesis, prion disease.

« Previous Next »

Graphical Abstract

Graphical abstract illustrating key findings of the study

[1]
Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the common neurodegenerative disorders: Current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci 2022; 23(3): 1851.
[http://dx.doi.org/10.3390/ijms23031851] [PMID: 35163773]
[2]
Jankovska N, Rusina R, Bruzova M, Parobkova E, Olejar T, Matej R. Human prion disorders: Review of the current literature and a twenty-year experience of the national surveillance center in the czech republic. Diagnostics 2021; 11(10): 1821.
[http://dx.doi.org/10.3390/diagnostics11101821] [PMID: 34679519]
[3]
Geschwind MD. Prion diseases. Continuum 2015; 21(6): 1612-38.
[http://dx.doi.org/10.1212/CON.0000000000000251]
[4]
Satoh K. CSF biomarkers for prion diseases. Neurochem Int 2022; 155: 105306.
[http://dx.doi.org/10.1016/j.neuint.2022.105306] [PMID: 35176437]
[5]
Kranitz F, Simpson D. Using non-pharmacological approaches for CJD patient and family support as provided by the CJD foundation and CJD insight. CNS Neurol Disord Drug Targets 2009; 8(5): 372-9.
[http://dx.doi.org/10.2174/187152709789542005] [PMID: 19702572]
[6]
Sitammagari KK, Masood W. Creutzfeldt Jakob Disease. Treasure Island, FL: StatPearls Publishing 2024.
[7]
Chen C, Dong XP. Epidemiological characteristics of human prion diseases. Infect Dis Poverty 2016; 5(1): 47.
[http://dx.doi.org/10.1186/s40249-016-0143-8] [PMID: 27251305]
[8]
Weber DJ, Rutala WA. Managing the risk of nosocomial transmission of prion diseases. Curr Opin Infect Dis 2002; 15(4): 421-5.
[http://dx.doi.org/10.1097/00001432-200208000-00011] [PMID: 12130940]
[9]
Kennedy RH, Hogan RN, Brown P, et al. Eye banking and screening for Creutzfeldt-Jakob disease. Arch Ophthalmol 2001; 119(5): 721-6.
[http://dx.doi.org/10.1001/archopht.119.5.721] [PMID: 11346399]
[10]
Weinstein RA, Rutala WA, Weber DJ. Creutzfeldt-Jakob disease: Recommendations for disinfection and sterilization. Clin Infect Dis 2001; 32(9): 1348-56.
[http://dx.doi.org/10.1086/319997] [PMID: 11303271]
[11]
Ma Y, Ma J. Immunotherapy against Prion Disease. Pathogens 2020; 9(3): 216.
[http://dx.doi.org/10.3390/pathogens9030216] [PMID: 32183309]
[12]
Mead S, Khalili-Shirazi A, Potter C, et al. Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-Jakob disease: Evaluation of a first-in-human treatment programme. Lancet Neurol 2022; 21(4): 342-54.
[http://dx.doi.org/10.1016/S1474-4422(22)00082-5] [PMID: 35305340]
[13]
Liu F, Lü W, Liu L. New implications for prion diseases therapy and prophylaxis. Front Mol Neurosci 2024; 17: 1324702.
[http://dx.doi.org/10.3389/fnmol.2024.1324702] [PMID: 38500676]
[14]
Bamia A, Sinane M, Naït-Saïdi R, et al. Anti-prion drugs targeting the protein folding activity of the ribosome reduce PABPN1 aggregation. Neurotherapeutics 2021; 18(2): 1137-50.
[http://dx.doi.org/10.1007/s13311-020-00992-6] [PMID: 33533011]
[15]
Ayeni EA, Aldossary AM, Ayejoto DA, et al. Neurodegenerative diseases: Implications of environmental and climatic influences on neurotransmitters and neuronal hormones activities. Int J Environ Res Public Health 2022; 19(19): 12495.
[http://dx.doi.org/10.3390/ijerph191912495] [PMID: 36231792]
[16]
Gallardo M, Delgado F. Animal prion diseases: A review of intraspecies transmission. Open Vet J 2021; 11(4): 707-23.
[http://dx.doi.org/10.5455/OVJ.2021.v11.i4.23] [PMID: 35070868]
[17]
Baiardi S, Mammana A, Capellari S, Parchi P. Human prion disease: Molecular pathogenesis, and possible therapeutic targets and strategies. Expert Opin Ther Targets 2023; 27(12): 1271-84.
[http://dx.doi.org/10.1080/14728222.2023.2199923] [PMID: 37334903]
[18]
Aguzzi A, Heppner FL. Pathogenesis of prion diseases: A progress report. Cell Death Differ 2000; 7(10): 889-902.
[http://dx.doi.org/10.1038/sj.cdd.4400737] [PMID: 11279534]
[19]
Benarroch E. What are the roles of cellular prion protein in normal and pathologic conditions? Neurology 2024; 102(7): 209272.
[http://dx.doi.org/10.1212/WNL.0000000000209272] [PMID: 38484222]
[20]
Appleby BS, Shetty S, Elkasaby M. Genetic aspects of human prion diseases. Front Neurol 2022; 13: 1003056.
[http://dx.doi.org/10.3389/fneur.2022.1003056] [PMID: 36277922]
[21]
Ladogana A, Kovacs GG. Genetic Creutzfeldt–Jakob disease. Handb Clin Neurol 2018; 153: 219-42.
[http://dx.doi.org/10.1016/B978-0-444-63945-5.00013-1] [PMID: 29887139]
[22]
Ghetti B, Piccardo P, Zanusso G. Dominantly inherited prion protein cerebral amyloidoses – a modern view of Gerstmann–Sträussler-Scheinker. Handb Clin Neurol 2018; 153: 243-69.
[http://dx.doi.org/10.1016/B978-0-444-63945-5.00014-3] [PMID: 29887140]
[23]
Cracco L, Appleby BS, Gambetti P. Fatal familial insomnia and sporadic fatal insomnia. Handb Clin Neurol 2018; 153: 271-99.
[http://dx.doi.org/10.1016/B978-0-444-63945-5.00015-5] [PMID: 29887141]
[24]
Bagyinszky E, Giau VV, Youn YC, A An SS, Kim S. Characterization of mutations in PRNP (prion) gene and their possible roles in neurodegenerative diseases. Neuropsychiatr Dis Treat 2018; 14: 2067-85.
[http://dx.doi.org/10.2147/NDT.S165445] [PMID: 30147320]
[25]
Rayi A, Murr NI. Electroencephalogram. Treasure Island, FL: StatPearls Publishing 2024.
[26]
Altuna M, Ruiz I, Zelaya MV, Mendioroz M. Role of biomarkers for the diagnosis of prion diseases: A narrative review. Medicina 2022; 58(4): 473.
[http://dx.doi.org/10.3390/medicina58040473] [PMID: 35454316]
[27]
Wieser H, Schindler K, Zumsteg D. EEG in creutzfeldt–jakob disease. Clin Neurophysiol 2006; 117(5): 935-51.
[http://dx.doi.org/10.1016/j.clinph.2005.12.007] [PMID: 16442343]
[28]
Sacco S, Paoletti M, Staffaroni AM, et al. Multimodal MRI staging for tracking progression and clinical-imaging correlation in sporadic Creutzfeldt-Jakob disease. Neuroimage Clin 2021; 30: 102523.
[http://dx.doi.org/10.1016/j.nicl.2020.102523] [PMID: 33636540]
[29]
Alsiary RA, Alghrably M, Saoudi A, et al. Using NMR spectroscopy to investigate the role played by copper in prion diseases. Neurol Sci 2020; 41(9): 2389-406.
[http://dx.doi.org/10.1007/s10072-020-04321-9] [PMID: 32328835]
[30]
Biljan I, Ilc G, Plavec J. Understanding the Effect of Disease-Related Mutations on Human Prion Protein Structure: Insights From NMR Spectroscopy. Prog Mol Biol Transl Sci 2017; 150: 83-103.
[http://dx.doi.org/10.1016/bs.pmbts.2017.06.006] [PMID: 28838676]
[31]
Telano LN, Baker S. Physiology, Cerebral Spinal Fluid. Treasure Island, FL: StatPearls Publishing 2024.
[32]
Berg D, Holzmann C, Riess O. 14-3-3 proteins in the nervous system. Nat Rev Neurosci 2003; 4(9): 752-62.
[http://dx.doi.org/10.1038/nrn1197] [PMID: 12951567]
[33]
Hermann P, Appleby B, Brandel JP, et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol 2021; 20(3): 235-46.
[http://dx.doi.org/10.1016/S1474-4422(20)30477-4] [PMID: 33609480]
[34]
Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: Diagnostic accuracy of CSF 14-3-3 protein in sporadic creutzfeldt-jakob disease. Neurology 2012; 79(14): 1499-506.
[http://dx.doi.org/10.1212/WNL.0b013e31826d5fc3] [PMID: 22993290]
[35]
Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci 2016; 17(1): 22-35.
[http://dx.doi.org/10.1038/nrn.2015.1] [PMID: 26631930]
[36]
Thompson AGB, Mead SH. Review: Fluid biomarkers in the human prion diseases. Mol Cell Neurosci 2019; 97: 81-92.
[http://dx.doi.org/10.1016/j.mcn.2018.12.003] [PMID: 30529227]
[37]
Zerr I, Villar-Piqué A, Schmitz VE, et al. Evaluation of human cerebrospinal fluid malate dehydrogenase 1 as a marker in genetic prion disease patients. Biomolecules 2019; 9(12): 800.
[http://dx.doi.org/10.3390/biom9120800] [PMID: 31795176]
[38]
Lieberman PL, Settipane RA. Azelastine nasal spray: A review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis. Allergy Asthma Proc 2003; 24(2): 95-105.
[PMID: 12776442]
[39]
Dhaliwal JS, Spurling BC, Molla M. Duloxetine. Treasure Island, FL: StatPearls Publishing 2024.
[40]
Sastre J. Ebastine in the treatment of allergic rhinitis and urticaria: 30 years of clinical studies and real-world experience. J Investig Allergol Clin Immunol 2020; 30(3): 156-68.
[http://dx.doi.org/10.18176/jiaci.0401] [PMID: 30977465]
[41]
Pubchem compound summary for CID 941361, flunarizine. 2021. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Flunarizine
[42]
Sahi N, Nguyen R, Patel P. Loperamide. Treasure Island, FL: StatPearls Publishing 2024.
[43]
Pubchem compound summary for CID 4167, metixene. 2021. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Metixene
[44]
Maille JM, Hanna SS, Shah DN. Addition of clobazam successfully treating drug resistant seizures in Heidenhain variant Creutzfeldt Jakob disease: A case report. Epilepsy Behav Rep 2023; 21: 100585.
[http://dx.doi.org/10.1016/j.ebr.2023.100585] [PMID: 36698381]
[45]
Price JR, Kheirbek RE. Addressing the unmet needs of patients with rapidly progressive neurological disease: A case report of palliative care in creutzfeldt-jakob disease (CJD). Cureus 2024; 16(2): 55228.
[http://dx.doi.org/10.7759/cureus.55228] [PMID: 38558630]
[46]
Tabaee Damavandi P, Dove MT, Pickersgill RW. A review of drug therapy for sporadic fatal insomnia. Prion 2017; 11(5): 293-9.
[http://dx.doi.org/10.1080/19336896.2017.1368937] [PMID: 28976233]
[47]
Appleby BS, Yobs DR. Symptomatic treatment, care, and support of CJD patients. Handb Clin Neurol 2018; 153: 399-408.
[http://dx.doi.org/10.1016/B978-0-444-63945-5.00021-0] [PMID: 29887147]
[48]
Minikel EV, Zhao HT, Le J, et al. Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucleic Acids Res 2020; 48(19): 10615-31.
[http://dx.doi.org/10.1093/nar/gkaa616] [PMID: 32776089]
[49]
Wagner J, Ryazanov S, Leonov A, et al. Anle138b: A novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease. Acta Neuropathol 2013; 125(6): 795-813.
[http://dx.doi.org/10.1007/s00401-013-1114-9] [PMID: 23604588]
[50]
Shim KH, Sharma N, An SSA. Prion therapeutics: Lessons from the past. Prion 2022; 16(1): 265-94.
[http://dx.doi.org/10.1080/19336896.2022.2153551] [PMID: 36515657]
[51]
Abdelaziz DH, Abdulrahman BA, Gilch S, Schatzl HM. Autophagy pathways in the treatment of prion diseases. Curr Opin Pharmacol 2019; 44: 46-52.
[http://dx.doi.org/10.1016/j.coph.2019.04.013] [PMID: 31096117]
[52]
Napper S, Schatzl HM. Vaccines for prion diseases: A realistic goal? Cell Tissue Res 2023; 392(1): 367-92.
[http://dx.doi.org/10.1007/s00441-023-03749-7] [PMID: 36764940]
[53]
Varges D, Manthey H, Heinemann U, et al. Doxycycline in early CJD: A double-blinded randomised phase II and observational study. J Neurol Neurosurg Psychiatry 2017; 88(2): 119-25.
[http://dx.doi.org/10.1136/jnnp-2016-313541] [PMID: 27807198]
[54]
McNiven K, Nihat A, Mok TH, et al. Enteral feeding is associated with longer survival in the advanced stages of prion disease. Brain Commun 2019; 1(1): fcz012.
[http://dx.doi.org/10.1093/braincomms/fcz012] [PMID: 32954259]
[55]
Goldman JS, Vallabh SM. Genetic counseling for prion disease: Updates and best practices. Genet Med 2022; 24(10): 1993-2003.
[http://dx.doi.org/10.1016/j.gim.2022.06.003] [PMID: 35819418]
[56]
Tsuboi Y, Doh-ura K, Yamada T. Continuous intraventricular infusion of pentosan polysulfate: Clinical trial against prion diseases. Neuropathology 2009; 29(5): 632-6.
[http://dx.doi.org/10.1111/j.1440-1789.2009.01058.x] [PMID: 19788637]
[57]
Takatsuki H, Imamura M, Mori T, Atarashi R. Pentosan polysulfate induces low-level persistent prion infection keeping measurable seeding activity without PrP-res detection in Fukuoka-1 infected cell cultures. Sci Rep 2022; 12(1): 7923.
[http://dx.doi.org/10.1038/s41598-022-12049-z] [PMID: 35562591]
[58]
Medd MM, Cao Q. Perspectives on CRISPR genome editing to prevent prion diseases in high-risk individuals. Biomedicines 2024; 12(8): 1725.
[http://dx.doi.org/10.3390/biomedicines12081725] [PMID: 39200190]
[59]
Du Z, Valtierra S, Cardona LR, Dunne SF, Luan CH, Li L. Identifying anti-prion chemical compounds using a newly established yeast high-throughput screening system. Cell Chem Biol 2019; 26(12): 1664-1680.e4.
[http://dx.doi.org/10.1016/j.chembiol.2019.10.004] [PMID: 31668517]
[60]
McDonnell G, Dehen C, Perrin A, et al. Cleaning, disinfection and sterilization of surface prion contamination. J Hosp Infect 2013; 85(4): 268-73.
[http://dx.doi.org/10.1016/j.jhin.2013.08.003] [PMID: 24074640]
[61]
Bovine spongiform encephalopathy (BSE). 2024. Available from: https://www.cdc.gov/mad-cow/php/animal-health/index.html
[62]
Addressing foodborne threats to health: Policies, practices, and global coordination: Workshop summary. 2006. Available from: https://www.ncbi.nlm.nih.gov/books/NBK57084/
[63]
All about BSE (mad cow disease). 2020. Available from: https://www.fda.gov/animal-veterinary/animal-health-literacy/all-about-bse-mad-cow-disease
[64]
Kufel J, Bargieł-Łączek K, Kocot S, et al. What is machine learning, artificial neural networks and deep learning?—examples of practical applications in medicine. Diagnostics 2023; 13(15): 2582.
[http://dx.doi.org/10.3390/diagnostics13152582] [PMID: 37568945]
[65]
Lepakshi VA. Machine learning and deep learning based AI tools for development of diagnostic tools. In: Parihar A, Khan R, Kumar A, Eds. Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2 Infection. United States: Academic Press 2022; pp. 399-420.
[http://dx.doi.org/10.1016/B978-0-323-91172-6.00011-X]
[66]
Salvi M, Molinari F, Ciccarelli M, Testi R, Taraglio S, Imperiale D. Quantitative analysis of prion disease using an AI-powered digital pathology framework. Sci Rep 2023; 13(1): 17759.
[http://dx.doi.org/10.1038/s41598-023-44782-4] [PMID: 37853094]
[67]
Rajagopal BG, Arock M. Application of machine learning techniques for study of drug interactions using clinical parameters for creutzfeldt-jakob disease. 2020 IEEE-EMBS Conference on Biomedical Engineering and Sciences (IECBES). 2021, pp. 415-420.
[http://dx.doi.org/10.1109/IECBES48179.2021.9398847]
[68]
Watson N, Kurudzhu H, Green A, Summers D, Smith C, Pal S. Application of telehealth for comprehensive Creutzfeldt-Jakob disease surveillance in the United Kingdom. J Neurol Sci 2021; 420: 117221.
[http://dx.doi.org/10.1016/j.jns.2020.117221] [PMID: 33223148]
[69]
Geissen M, Leidel F, Eiden M, et al. From high-throughput cell culture screening to mouse model: Identification of new inhibitor classes against prion disease. ChemMedChem 2011; 6(10): 1928-37.
[http://dx.doi.org/10.1002/cmdc.201100119] [PMID: 21755599]
[70]
Ishibashi D, Ishikawa T, Mizuta S, et al. Novel compounds identified by structure-based prion disease drug discovery using in silico screening delay the progression of an illness in prion-infected mice. Neurotherapeutics 2020; 17(4): 1836-49.
[http://dx.doi.org/10.1007/s13311-020-00903-9] [PMID: 32767031]
[71]
Ishibashi D, Nakagaki T, Ishikawa T, et al. Structure-based drug discovery for prion disease using a novel binding simulation. EBioMedicine 2016; 9: 238-49.
[http://dx.doi.org/10.1016/j.ebiom.2016.06.010] [PMID: 27333028]
[72]
Ali T, Hannaoui S, Nemani S, et al. Oral administration of repurposed drug targeting Cyp46A1 increases survival times of prion infected mice. Acta Neuropathol Commun 2021; 9(1): 58.
[http://dx.doi.org/10.1186/s40478-021-01162-1] [PMID: 33795005]
[73]
Jiang D, Nan H, Chen Z, Zou WQ, Wu L. Genetic insights into drug targets for sporadic Creutzfeldt-Jakob disease: Integrative multi-omics analysis. Neurobiol Dis 2024; 199: 106599.
[http://dx.doi.org/10.1016/j.nbd.2024.106599] [PMID: 38996988]
[74]
Vanni S. Omics of prion diseases. Prog Mol Biol Transl Sci 2017; 150: 409-31.
[http://dx.doi.org/10.1016/bs.pmbts.2017.05.004] [PMID: 28838672]
[75]
Casey C, Sleator RD. Prions: Structure, function, evolution, and disease. Arch Microbiol 2025; 207(1): 1.
[http://dx.doi.org/10.1007/s00203-024-04200-3] [PMID: 39572454]
[76]
Canas LS, Sudre CH, De Vita E, et al. Prion disease diagnosis using subject-specific imaging biomarkers within a multi-kernel Gaussian process. Neuroimage Clin 2019; 24: 102051.
[http://dx.doi.org/10.1016/j.nicl.2019.102051] [PMID: 31734530]
[77]
Abdallah S, Sharifa M, I Kh Almadhoun MK, et al. The impact of artificial intelligence on optimizing diagnosis and treatment plans for rare genetic disorders. Cureus 2023; 15(10): 46860.
[http://dx.doi.org/10.7759/cureus.46860] [PMID: 37954711]
[78]
Rossi M, Baiardi S, Parchi P. Understanding prion strains: Evidence from studies of the disease forms affecting humans. Viruses 2019; 11(4): 309.
[http://dx.doi.org/10.3390/v11040309] [PMID: 30934971]
[79]
Kurt TD, Sigurdson CJ. Cross-species transmission of CWD prions. Prion 2016; 10(1): 83-91.
[http://dx.doi.org/10.1080/19336896.2015.1118603] [PMID: 26809254]
[80]
Eid S, Lee S, Verkuyl CE, et al. The importance of prion research. Biochem Cell Biol 2024; 102(6): 448-71.
[http://dx.doi.org/10.1139/bcb-2024-0018] [PMID: 38996387]
[81]
Gambetti P, Kong Q, Zou W, Parchi P, Chen SG. Sporadic and familial CJD: Classification and characterisation. Br Med Bull 2003; 66(1): 213-39.
[http://dx.doi.org/10.1093/bmb/66.1.213] [PMID: 14522861]
[82]
Samek W, Wiegand T, Müller K. Explainable artificial intelligence: Understanding, visualizing and interpreting deep learning models. 2017. Available from: https://arxiv.org/abs/1708.08296
[83]
Teruya K, Doh-ura K. Insights from therapeutic studies for prp prion disease. Cold Spring Harb Perspect Med 2017; 7(3): a024430.
[http://dx.doi.org/10.1101/cshperspect.a024430] [PMID: 27836910]
[84]
Collins SD. Discontinued drugs in 2006: Central and peripheral nervous system drugs. Expert Opin Investig Drugs 2007; 16(11): 1743-51.
[http://dx.doi.org/10.1517/13543784.16.11.1743] [PMID: 17970635]
[85]
Zerr I, Poser S. Clinical diagnosis and differential diagnosis of CJD and vCJD. Acta Pathol Microbiol Scand Suppl 2002; 110(1): 88-98.
[http://dx.doi.org/10.1034/j.1600-0463.2002.100111.x] [PMID: 12064260]
[86]
Baldwin KJ, Correll CM. Prion disease. Semin Neurol 2019; 39(4): 428-39.
[http://dx.doi.org/10.1055/s-0039-1687841] [PMID: 31533183]
[87]
Ironside JW, Ritchie DL, Head MW. Prion diseases. Handb Clin Neurol 2018; 145: 393-403.
[http://dx.doi.org/10.1016/B978-0-12-802395-2.00028-6] [PMID: 28987186]
[88]
Piñar-Morales R, Barrero-Hernández F, Aliaga-Martínez L. Human prion diseases: An overview. Medic Clin 2023; 160(12): 554-60.
[http://dx.doi.org/10.1016/j.medcli.2023.03.001]
[89]
Orrú CD, Groveman BR, Raymond LD, et al. Bank vole prion protein as an apparently universal substrate for RT-quic-based detection and discrimination of prion strains. PLoS Pathog 2015; 11(6): 1004983.
[http://dx.doi.org/10.1371/journal.ppat.1004983] [PMID: 26086786]
[90]
Meyne F, Gloeckner SF, Ciesielczyk B, et al. Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. J Alzheimers Dis 2009; 17(4): 863-73.
[http://dx.doi.org/10.3233/JAD-2009-1110] [PMID: 19542614]
[91]
Steinhoff BJ, Zerr I, Glatting M, Schulz-Schaeffer W, Poser S, Kretzschmar HA. Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol 2004; 56(5): 702-8.
[http://dx.doi.org/10.1002/ana.20261] [PMID: 15449324]
[92]
Zerr I, Bodemer M, Gefeller O, et al. Detection of 14‐3‐3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt‐Jakob disease. Ann Neurol 1998; 43(1): 32-40.
[http://dx.doi.org/10.1002/ana.410430109] [PMID: 9450766]
[93]
Knight R, Brazier M, Collins SJ. Human prion diseases: Cause, clinical and diagnostic aspects. Contrib Microbiol 2004; 11: 72-97.
[http://dx.doi.org/10.1159/000077051] [PMID: 15077404]
[94]
Haïk S, Marcon G, Mallet A, et al. Doxycycline in Creutzfeldt-Jakob disease: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13(2): 150-8.
[http://dx.doi.org/10.1016/S1474-4422(13)70307-7] [PMID: 24411709]
[95]
White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003; 422(6927): 80-3.
[http://dx.doi.org/10.1038/nature01457] [PMID: 12621436]
[96]
Daude N, Westaway D. Shadoo/PrP (Sprn0/0/Prnp0/0) double knockout mice. Prion 2012; 6(5): 420-4.
[http://dx.doi.org/10.4161/pri.21867] [PMID: 22929230]
[97]
Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P. Sporadic human prion diseases: Molecular insights and diagnosis. Lancet Neurol 2012; 11(7): 618-28.
[http://dx.doi.org/10.1016/S1474-4422(12)70063-7] [PMID: 22710755]
[98]
Bradford BM, Piccardo P, Ironside JW, Mabbott NA. Human prion diseases and the risk of their transmission during anatomical dissection. Clin Anat 2014; 27(6): 821-32.
[http://dx.doi.org/10.1002/ca.22403] [PMID: 24740900]
[99]
Outeiro TF, Höglinger G, Lang AE, Vieira TCRG. Protein misfolding: Understanding biology to classify and treat synucleinopathies. J Neural Transm 2025; 1-6.
[http://dx.doi.org/10.1007/s00702-025-02889-0] [PMID: 39932548]
[100]
Zhao Y, Jaber VR, Lukiw WJ. SARS-CoV-2, long COVID, prion disease and neurodegeneration. Front Neurosci 2022; 16: 1002770.
[http://dx.doi.org/10.3389/fnins.2022.1002770] [PMID: 36238082]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 41
Html icon 1
Find your institution